UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000056609
Receipt number R000064676
Scientific Title Evaluation of the Effectiveness of a Peer-Support Habit-Forming App Intervention on HbA1c Improvement in Patients with Type 2 diabetes mellitus
Date of disclosure of the study information 2025/01/10
Last modified on 2024/12/31 09:41:40

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of the Effect of a Peer-Support App on HbA1c Improvement in Patients with Type 2 diabetes mellitus

Acronym

Evaluation of the HbA1c Improvement Effect of a Peer-Support App

Scientific Title

Evaluation of the Effectiveness of a Peer-Support Habit-Forming App Intervention on HbA1c Improvement in Patients with Type 2 diabetes mellitus

Scientific Title:Acronym

Evaluation of the HbA1c Improvement Effect of a Peer-Support App

Region

Japan


Condition

Condition

Type 2 diabetes mellitus

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to evaluate the effect of a peer-support habit-forming app on HbA1c levels in patients with Type 2 diabetes mellitus, whose baseline HbA1c levels range from 7.0% to 8.4%. Patients will be randomly assigned to either the app usage group or the non-usage group. The intervention will be conducted over a period of 24 weeks, in addition to standard medical care and guidance provided by physicians.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Between-group comparison of changes in HbA1c levels from baseline to week 24 of the treatment period

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

The app usage group will share blood glucose management reports in teams of five and conduct measurements of body weight, blood pressure, and blood tests at 12 and 24 weeks.

Interventions/Control_2

The non-usage group will work on achieving their goals individually without sharing results. Measurements of body weight, blood pressure, and blood tests will be conducted at 12 and 24 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

74 years-old >=

Gender

Male and Female

Key inclusion criteria

1.Aged 18 to 74 years
2.Patients with type 2 diabetes mellitus, HbA1c between 7.0% and 8.4%
3.Possess a smartphone capable of installing and operating the app

Key exclusion criteria

1.Difficulty communicating in Japanese
2.Unable to walk independently
3.Previously used this app

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Kyoichiro
Middle name
Last name Tsuchiya

Organization

University of Yamanashi Hospital

Division name

Department of Diabetes and Endocrinology

Zip code

409-3898

Address

1110 Shimokato, Chuo-shi, Yamanashi

TEL

055-273-3310

Email

tsuchiyak@yamanashi.ac.jp


Public contact

Name of contact person

1st name Nozomi
Middle name
Last name Harai

Organization

University of Yamanashi Hospital

Division name

Department of Diabetes and Endocrinology

Zip code

409-3898

Address

1110 Shimokato, Chuo-shi, Yamanashi

TEL

0552733310

Homepage URL


Email

knozomi@yamanashi.ac.jp


Sponsor or person

Institute

University of Yamanashi Hospital

Institute

Department

Personal name



Funding Source

Organization

A10 Lab Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Yamanashi Prefectural Central Hospital
Enzan Citizen Hospital
Ichikawa Medical Clinic
Kitamura Clinic
Nakazato Medical Clinic
National Hospital Organization Kofu National Hospital
Fuefuki Central Hospital
Chuo Internal Medicine Clinic
Fujiyoshida Municipal Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization

University of Yamanashi

Address

University of Yamanashi

Tel

055-273-1111

Email

rec-med@yamanashi.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 01 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

112

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2023 Year 05 Month 01 Day

Date of IRB

2023 Year 06 Month 07 Day

Anticipated trial start date

2023 Year 08 Month 01 Day

Last follow-up date

2025 Year 02 Month 28 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2024 Year 12 Month 31 Day

Last modified on

2024 Year 12 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064676